A new report has predicted that the global antibiotics market will grow at a CAGR of four percent from 2020-2027.
List view / Grid view
Filter the results
Abbott Laboratories is an American worldwide healthcare company. With headquarters in Lake Bluff, Illinois, it has 94,000 employees and operates in more than 150 countries.
The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; it eventually grew to also sell research-based drugs, medical devices, diagnostics, and nutritional products. It split off the research-based pharmaceuticals into Abbvie in 2013. In 2015, revenues were $20.4 billion.
Abbott has a broad range of branded generic pharmaceuticals, medical devices, diagnostics, and nutrition products. The company’s in-vitro diagnostics business performs immunoassays and blood screening. Its medical tests and diagnostic instrument systems are used worldwide by hospitals, laboratories, blood banks, and physician offices to diagnose and monitor diseases such as HIV, hepatitis, cancer, heart failure and metabolic disorders, as well as assess other indicators of health. In 1985, the company developed the first HIV blood-screening test.
Rising at a CAGR of 8.2 percent, the rapid microbiology testing market is predicted to grow over the next five years.
The new quantitative SARS-CoV-2 IgG lab-based serology test developed by Abbott has been given the CE mark.
FDA approves new heart rhythm devices featuring Bluetooth connectivity and continuous remote monitoring
Abbott’s Gallant™ implantable cardioverter defibrillator (ICD) and cardiac resynchronisation therapy defibrillator (CRT-D) devices are given approval.
Abbott has revealed its SARS-CoV-2 antibody test was not designed for at home use despite companies selling them for this purpose. Also, what do experts think about these tests?
3 February 2017 | By Niamh Marriott, Digital Editor
The US Food and Drug Administration (FDA) has authorised Abbott’s molecular test to detect Zika virus in whole blood (when collected alongside a patient-matched serum or plasma sample) for emergency use. This is the first molecular test made by a commercial manufacturer authorised to detect Zika in whole blood samples;…
16 March 2016 | By Victoria White
Absorb is a first-of-its-kind bioresorbable device for the treatment of coronary artery disease. It dissolves completely after 2 to 3 years...
2 September 2015 | By Victoria White
ABSORB Japan, a trial comparing the safety and effectiveness of Abbott's fully dissolving Absorb heart stent to Xience, has produced positive results...
1 September 2015 | By Nick Jackson
Abbott has announced positive one-year clinical results from ABSORB Japan, a multi-center, randomised trial comparing the safety and effectiveness of Abbott's fully dissolving AbsorbTM heart stent to XIENCE®...
24 August 2015 | By Victoria White
New data from Abbott's Concussion IQ Survey reveals that many adults lack basic understanding about concussion signs, symptoms, risk and treatment...
2 February 2015 | By Abbott
The US FDA has approved two new TECNIS® multifocal intraocular lenses, allowing people with cataracts to choose the best option for their lifestyle...
Abbott commences tender Offer and Consent Solicitation for CFR International SpA 5.125% Senior Notes due 2022
16 December 2014 | By Abbott
Abbott announced that its wholly-owned subsidiary, Abbott Laboratories (Chile) Holdco (Dos) SpA, a Chilean corporation ("ALH"), has commenced a tender offer (the "U.S. Notes Offer"), in which it is offering to purchase for cash any and all of the outstanding $300 million aggregate principal amount of 5.125% Senior Notes due…